REG - AstraZeneca PLC - Block listing Interim Review

AstraZenecaAnnouncement

03/12/2018 16:00

RNS Number : 2809J
AstraZeneca PLC
03 December 2018
 


3 December 2018 16:00 GMT
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date: 3 December 2018
 



Name of applicant:


ASTRAZENECA PLC




Name of scheme:


ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME




Period of return:


From:


1 June 2018


To:


30 November 2018




Balance of unallotted securities under scheme(s) from previous return:


1,991,308




Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):


0




Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):


164,291




Equals: Balance under scheme(s) not yet issued/allotted at end of period:


1,827,017










 



Name of contact:


CAMILLA WISEMAN




Telephone number of contact:


020 3749 5000



 
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 
 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 



Media Relations












Karen Birmingham


UK/Global


+44 203 749 5634




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Gonzalo Viña


UK/Global


+44 203 749 5916




Jennifer Hursit


UK/Global


+44 7384 799 726




Jacob Lund


Sweden


+46 8 553 260 20




Michele Meixell


US


+1 302 885 2677


















Investor Relations












Thomas Kudsk Larsen






+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


Cardiovascular; Metabolism


+44 203 749 5711




Nick Stone


Respiratory; Renal


+44 203 749 5716




Josie Afolabi


Other


+44 203 749 5631




Craig Marks


Finance; Fixed Income


+44 7881 615 764




Jennifer Kretzmann


Retail Investors


+44 203 749 5824




US toll-free






+1 866 381 7277

















Adrian Kemp

Company Secretary
AstraZeneca PLC
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRFSDFIDFASELE